Key Insights

Highlights

Success Rate

84% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

4.8%

5 terminated out of 104 trials

Success Rate

83.9%

-2.7% vs benchmark

Late-Stage Pipeline

4%

4 trials in Phase 3/4

Results Transparency

19%

5 of 26 completed with results

Key Signals

5 with results84% success

Data Visualizations

Phase Distribution

54Total
Not Applicable (37)
Early P 1 (2)
P 1 (6)
P 2 (5)
P 3 (1)
P 4 (3)

Trial Status

Recruiting37
Not Yet Recruiting27
Completed26
Active Not Recruiting5
Terminated5
Enrolling By Invitation3

Trial Success Rate

83.9%

Benchmark: 86.6%

Based on 26 completed trials

Clinical Trials (104)

Showing 20 of 20 trials
NCT07752446Not ApplicableRecruiting

Mediterranean Diet and Time-Restricted Feeding in Ulcerative Colitis Remission

NCT07237516Recruiting

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

NCT07368972Phase 2RecruitingPrimary

Study of DISC-0974-201 in Participants With IBD and Anemia

NCT07716488Not ApplicableRecruiting

Screening for Disorders of Lipid Metabolism and Familial Hyperlipidemia in Children and Adolescents With Increased Cardiovascular Risk Due to Chronic Diseases Such as Congenital Heart Disease, Chronic Inflammatory Bowel Disease, Celiac Disease and Rheumatic Disorders

NCT07224113Recruiting

Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBD

NCT07697547CompletedPrimary

Efficacy and Safety of Low-Dose Upadacitinib Combined With Ustekinumab in the Treatment of Refractory Crohn's Disease

NCT07245394RecruitingPrimary

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

NCT07681895Not Yet RecruitingPrimary

Biophysical Assessments of Acupuncture Points in Inflammatory Bowel Disease

NCT07682038Not Yet Recruiting

Retrospective Observational Multicenter Study on the Treatment Patterns, Extra-Intestinal Manifestations, Resource Utilisation, and Outcomes of Patients With Inflammatory Bowel Disease in Dutch Hospitals

NCT07676136Not ApplicableNot Yet Recruiting

A Pilot Study Using Gut-Directed Hypnotherapy for Hospitalized Patients

NCT07647640Not Yet RecruitingPrimary

Prospective Evaluation of Flare Detection in IBD With Digital Biomarkers: Bring Your Own Device Study

NCT06793124Recruiting

Comparison Diagnostic Tests for the Diagnosis of CYTOmegalovirus Organ Disease in Patients With intestinalBOweL Diseases

NCT06657001Enrolling By InvitationPrimary

Enabling Microbiomics- Driven Personalized Nutrition

NCT07619638Not ApplicableRecruiting

AIM-IBD: A Microbiome-Targeted Supplement in Mild-to-Moderate Ulcerative Colitis

NCT06944873Not Yet RecruitingPrimary

Metabolic Reprogramming of Monocytes in Inflammatory Flares of Inflammatory Bowel Diseases

NCT07590518Not ApplicableNot Yet RecruitingPrimary

VR Therapies for IBD

NCT07221890Not ApplicableActive Not Recruiting

A Trial of Academic Detailing to Promote Prescribing of Biosimilars

NCT07123350Active Not RecruitingPrimary

Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease

NCT06683105Not ApplicableRecruitingPrimary

Clinical Investigation of MYIBDDiet App Developed for Inflammatory Bowel Disease (IBD) Patients to Self-manage Their Diet

NCT05384080CompletedPrimary

A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Poland

Scroll to load more

Research Network

Activity Timeline